Intravenous Injection of Nrf2 Plasmid Attenuates Glomerular ROS Injury of Diabetic Mice

Li Hang,Cao Yanping,Feng Hong,Ren Yunzhuo,Liu Qingjuan,Liu Ronghui,Zhang Lianshan
2011-01-01
Abstract:This study aimed at examining the effects of treatment with streptozotocin(STZ)-induced diabetic mice by intravenous inchina with Nuclear factor erythroid 2-related factor 2(Nrf2) plasmid via mouse tail vein on diabetic nephropathy(DN) and the potential mechanisms underlying the action of Nrf2.Male CD-1 mice were randomly assigned to four groups:control group(group C);diabetes mellitus group(group DM);diabetes+pcDNA3 plasmid injection group(group DM+V);diabetes+pcDNA3/mNrf2 plasmid injection group(group DM+N).The model of DM was induced by single-dose intraperitoneal injection of streptozocin(STZ).Mice of group DM+V and group DM+N were injected with a shot of pcDNA3 plasmid or pcDNA3/mNrf2 plasmid via mouse tail vein three days after model establishment,respectively.Four weeks later,malondialdehyde(MDA) contents,the expressions of fibronectin(FN),Nrf2,γ-glutamylcysteine synthethase(γ-GCS) in the glomeruli were detected.We found that Nrf2 could be up-expressed in renal glomeruli by intravenous injection with Nrf2 plasmid;intravenous injection with Nrf2 plasmid significantly reduced the levels of glomerular MDA concentration;mitigated the expression of FN,enhanced Nrf2 nuclear accumulation and target antioxidant gene y-GCS expression in the glomeruli of diabetic mice.All these results indicated that intravenous injection with Nrf2 plasmid could attenuate the hyperglycaemia-induced glomerular oxidative stress injury and reduce the extracellular matrix(ECM) deposition in diabetic mice.It could be useful for the further gene therapy study of diabetes in vivo.
What problem does this paper attempt to address?